<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01262898</url>
  </required_header>
  <id_info>
    <org_study_id>114479</org_study_id>
    <nct_id>NCT01262898</nct_id>
  </id_info>
  <brief_title>Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects With Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and
      MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up
      to 125 mg/day for 14 days were well tolerated with adverse events not occurring in greater
      prevalence than placebo, and no significant abnormal vital sign, ECG, or clinical laboratory
      findings. Pharmacokinetic parameters were linear and approximately dose proportional over the
      range of doses administered. Single doses of 50 mg - 150 mg GSK962040 significantly increased
      the rate of gastric emptying up to 40% as measured by the 13C octanoic acid stable isotope
      breath test. A similar effect of 50 mg and 125 mg on gastric emptying was observed throughout
      repeated dosing to healthy volunteers for 14-days.

      The aims of the present investigation (MOT114479) are to assess the pharmacodynamic effects
      (gastric emptying and symptoms), safety, tolerability, and pharmacokinetics of GSK962040
      after 28 days of once-daily dosing in Type I and Type II diabetic subjects with
      gastroparesis. An additional aim is to characterize the dose/exposure - pharmacodynamic
      effect relationship.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2011</start_date>
  <completion_date type="Actual">February 26, 2013</completion_date>
  <primary_completion_date type="Actual">February 26, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric Half Emptying Time (GEt1/2)</measure>
    <time_frame>Screening2/Baseline (Day -30 to -1) , Day 1, and Day 28</time_frame>
    <description>Gastric half emptying time is the time taken for half the contents of the stomach to empty. Gastric emptying was measured using the 13C-oral breath test, which is a tracer method that utilizes 13C, a non-radioactive isotope. Basal breath samples were obtained after an overnight fast or otherwise after 4 hours of fasting following a light meal. On Day 1 and Day 28, participants were then dosed with GSK962040 and additional breath test samples were taken prior to administration of a 13C-labelled test meal. The test meal was consumed approximately 80 minutes(min) later. After consumption of the test meal, breath samples were collected at pre-specified time points over an approximately 4 hour period following the test meal. For the duration of the breath test, no food or drink were allowed. The 13C breath content was determined by isotope ratio mass spectrometry. GE t1/2 was determined by using the cumulative percentage of the administered dose of 13C excreted in breath over 4 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With On-treatment Adverse Events (AES) and Serious Adverse Events(SAEs)</measure>
    <time_frame>Up to follow-up (5-10 days post last dose)</time_frame>
    <description>An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Data for on-treatment adverse events is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure(DBP) at Specified Time Points in Semi-supine Position</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>Blood pressure measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The Baseline value was Day 1 Pre-Dose values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate at Specified Time Points in Semi-supine Position</measure>
    <time_frame>Baseline, Day 1, and Day 8</time_frame>
    <description>Heart rate measurements were taken at pre-dose and 120 min (completion of meal) on Day 1 and Day 28. The Baseline value was Day 1 Pre-Dose values . Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiography Parameters (12-lead ECG)</measure>
    <time_frame>Baseline, Day 1 and Day 28</time_frame>
    <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 28. The Baseline value was the Day 1 pre-dose value. ECG parameters included PR interval, QRS duration, QT interval, QTcB, QTcF and RR interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Outside the Normal Range for SBP and DBP</measure>
    <time_frame>Screening2/Baseline (Day -30 to -1), Day 1 and 28</time_frame>
    <description>Blood pressure measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The clinical concern range (CCR) for SBP was greater than (&lt;) 85 and less than (&gt;) 160 and for DBP the range was &lt;45 and &gt;100. Data for semi-supine position has been presented. Baseline was Screening2/Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Outside the Normal Range for Heart Rate</measure>
    <time_frame>Screening2/Baseline (Day -30 to -1), Day 1 and 28</time_frame>
    <description>Heart rate measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The CCR for heart rate was Increase or decrease by less than or equal to (&gt;=) 15 and &gt;= 30. Data for semi-supine position has been presented. Baseline was Screening2/Baseline values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Outside the Normal Range for 12-lead ECG</measure>
    <time_frame>Baseline (Day 1 pre-dose), Day 1, Day 14 and Day 28</time_frame>
    <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 28. The CCR for ECG parameters were: PR interval (&lt;110 and &gt;220), QRS interval (&lt;75 and &gt;110), Absolute QTc interval (&gt;450 to =&lt; 480) respectively. Baseline was the pre-dose reading for Day 1. Data for abnormal- clinically significant (ACS) and abnormal- not clinically significant (ANCS) has been presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Chemistry: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Gamma Glutamyl Transferase, Creatine Kinase, Lactate Dehydrogenase</measure>
    <time_frame>Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28</time_frame>
    <description>Alkaline phosphatase, alanine amino transferase, aspartate amino transferase, gamma glutamyl transferase, creatine kinase, lactate dehydrogenase measurements were taken at Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Chemistry: Direct Bilirubin, Total Bilirubin, Creatinine, Uric Acid</measure>
    <time_frame>Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28</time_frame>
    <description>Direct Bilirubin, Total Bilirubin, Creatinine, Uric acid measurements were taken at Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Chemistry : Albumin, Total Protein</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Albumin, Total Protein measurements were taken at Baseline (Day 1 pre-dose), and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Clinical Chemistry : Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon Dioxide Content/Bicarbonate</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon dioxide content/Bicarbonate measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematology Parameters : Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet Count, White Blood Cell Count</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet count, White Blood cell count measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematology Parameters : Hematocrit</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Hematocrit measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Hemoglobin</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Mean Corpuscle Hemoglobin measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematology Parameters : Hemoglobin, Mean Corpuscle Hemoglobin Concentration</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Hemoglobin, Mean Corpuscle Hemoglobin concentration measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Volume</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Mean Corpuscle Volume measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematology Parameters : Red Blood Cell Count, Reticulocytes</measure>
    <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
    <description>Red Blood Cell count, Reticulocytes measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration AUC(0-t) at Specified Time Points</measure>
    <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
    <description>AUC(0-t) was derived from GSK962040 plasma concentration-time data. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.Only participants who received GSK962040 drug were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) at Specified Time Points</measure>
    <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
    <description>Cmax is defined as the maximum observed drug concentration after administration. Cmax was determined directly from the raw concentration-time data. Samples were collected at the following times: Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Occurrence of Cmax (Tmax) at Specified Time Points</measure>
    <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
    <description>Tmax is defined as the time to reach the observed maximum concentration. Samples were collected at the following times: Tmax was determined directly from the raw concentration-time data. Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ct) at Specified Time Points</measure>
    <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
    <description>Analysis of pre-dose (trough) concentration at the end of the dosing interval (Ct) was planned to be performed from the samples collected at Pre -dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance Following Oral Dosing (CL/F) at Specified Time Points</measure>
    <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
    <description>CL/F was calculated as dose/AUC. The parameter was planned to be analyzed from samples collected at Pre -dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however the data for this outcome measure was not collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (V/F) at Specified Time Points</measure>
    <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
    <description>The apparent volume of distribution V/F = CL/F Ã— MRT, where MRT is the mean residence time. The parameter was planned to be analyzed using samples collected at Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however, the data for this outcome measure was not collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-life (t1/2) at Specified Time Points</measure>
    <time_frame>The parameter was planned to be analyzed using samples collected at Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however, the data for this outcome measure was not collected.</time_frame>
    <description>This outcome measure was not analyzed in results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Bowel Movement After First Dose</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>The time to first bowel movement was calculated as the time of the first bowel movement after the first dose in hours (floored) for each participant. If a participant had fewer than 5 days worth of data then the daily mean for that week was set to missing for the following two parameters: Bowel Movement Count and Stool Consistency. Seventeen participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics of time to first bowel movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Bowel Movement Frequency</measure>
    <time_frame>Up to Week 4 (Day 28)</time_frame>
    <description>Daily bowel movement frequency analyzed number of times passed stools in 24 hours of duration. Following dosing with study medication, stool monitoring was performed up to Day 28. Seventeen participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Average Stool Consistency</measure>
    <time_frame>Up to Week 4 (Day 28)</time_frame>
    <description>Stool consistency was determined on a scale of 1 to 5 (1 = Very hard, 2 = Hard, 3 = Formed, 4 = Loose, 5 = Watery). Following dosing with study medication, stool monitoring was performed up to Day 28. Participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Upper Gastrointestinal (GI) Symptoms as Assessed by Total Gastrointestinal Cardinal Symptom Index - Daily Diary (GCSI-DD)</measure>
    <time_frame>Up to 14 days post last dose (Day 28)</time_frame>
    <description>GCSI-DD was measured on a 6-point scale. The Total GCSI-DD score was the mean of the following three subscales: Nausea/Vomiting Subscale = mean (nausea, retching, vomiting), Fullness/Early Satiety Subscale = mean (feeling excessively full after meals, not able to finish a normal-sized meal, stomach fullness, loss of appetite), Bloating Subscale = mean (bloating, stomach or belly visibly larger). Each subscale was scored on a severity scale of 0 (none) to 5 (very severe), with lower scores representing less symptom severity. The change from Baseline to each study week in average score was derived and if it improved by 1 point or more, that participant was defined as &quot;responder&quot; for that symptom and on that particular week. Baseline was Screening2/Baseline values (Day -30 to -1). Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)</measure>
    <time_frame>Baseline(Screening i.e., Day -30 to -1), Day 1 and 28</time_frame>
    <description>WMC is an ingestible telemetric capsule which measures pH, pressure and temperature to assess total gastric emptying time, small and large bowel transit time, colonic transit time, and whole gut transit time. The WMC was ingested immediately following the standard test meal for the oral breath test. Data was collected on a data logger, which was worn on a belt clip. The WMC passed naturally in the participant's stools between 2 and 5 days after ingestion. The parameters Whole bowel transit time, 100 % gastric emptying time (truncated at 240 minutes), small bowel transit time, colonic transit time were analyzed. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>GSK962040 (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK962040 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK962040 (50 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK962040 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK962040 (125 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK962040 125 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 (5 mg tablet)</intervention_name>
    <description>5 mg tablet</description>
    <arm_group_label>GSK962040 (10 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 (25 mg tablet)</intervention_name>
    <description>25 mg tablet</description>
    <arm_group_label>GSK962040 (50 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 (125 mg tablet)</intervention_name>
    <description>125 mg tablet</description>
    <arm_group_label>GSK962040 (125 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type I or II Diabetes Mellitus (HbA1C &lt; 10%)

          -  Male or female between 18 and 80 years of age, inclusive.

          -  Patient has gastroparesis at screening (gastric half-time of emptying &gt; upper limit of
             normal as determined by 13C-oral breath test)

          -  Patient must have a &gt; or = 3 month history of relevant symptoms of gastroparesis
             (e.g., chronic post-prandial fullness, early satiety, postprandial nausea), patients
             will have a mean of the daily scores over a minimum of 7 days indicating &gt; or = mild
             (2) and &lt; or = severe (4) post-prandial fullness assessed using the GCSI-DD during the
             screening period prior to randomization.

          -  A female patient is eligible to participate if she is of: Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or
             postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40 MlU/mL, or a
             value consistent with the local laboratory standard value, is confirmatory. OR
             Child-bearing potential and agrees to use one of the contraception methods listed in
             Section 8.1 for an appropriate period of time (as determined by the product label or
             investigator) prior to the start of dosing to sufficiently minimize the risk of
             pregnancy at that point. Female patients must agree to use contraception for at least
             5 days following the last dose of study medication.

          -  Male patients must agree to use one of the contraception methods listed in Section
             8.1. This criterion must be followed from the time of the first dose of study
             medication through at least 5 days after the last dose of study medication.

          -  BMI &gt;18 and &lt; or = 35.0 kg/m2 (inclusive).

          -  Patient has never had a gastrectomy, nor major gastric surgical procedure or any
             evidence of bowel obstruction or strictures within the previous 12 months

          -  Dosage of any concomitant medications has been stable for at least 3 weeks, except for
             routine adjustments in daily insulin treatments.

          -  Estimated (or measured) glomerular filtration rate &gt; or = 30 mL/min.

          -  QTcB or QTcF &lt; 450 msec or QTc &lt; 480 msec in patients with Bundle Branch Block based
             on single or average QTc value of triplicate values obtained over a brief recording
             period.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  AST and ALT &lt; 2xULN; alkaline phosphatase and bilirubin &lt; or = 1.5xULN (isolated
             bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin
             &lt;35%).

        Exclusion Criteria:

          -  Patient has acute severe gastroenteritis

          -  Patient has a gastric pacemaker

          -  Patient is on chronic parenteral feeding

          -  Patient has pronounced dehydration

          -  Recent (last 6 weeks) history of poor control of diabetes e.g. hypoglycaemia requiring
             medical intervention, diabetic ketoacidosis, admission for control diabetes or
             complications of diabetes

          -  Patient has evidence of severe cardiovascular autonomic neuropathy (e.g. history of
             recurrent syncope in the last 6 months)

          -  Patient has a history of eating disorders (anorexia nervosa, binge eating, bulimia)

          -  Use of medications potentially influencing upper gastrointestinal motility or appetite
             within one week of the study (e.g., prokinetic drugs, macrolide antibiotics
             (erythromycin), GLP-1 mimetics)

          -  Regular opiate use

          -  Use of prohibited medications listed in Section 9.2 within the restricted timeframe
             relative to the first dose of study medication.

          -  History or presence of clinically significant gastro-intestinal, hepatic or renal
             disease or other condition that would in the opinion of the investigator or medical
             monitor make the subject unsuitable for inclusion in this clinical study.

          -  The patient has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within a 56 day time-period.

          -  Pregnant females as determined by positive serum or urine hCG test (from the first
             urine of the day) at screening or prior to dosing.

          -  Lactating females.

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J 8L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2010</study_first_posted>
  <results_first_submitted>September 14, 2017</results_first_submitted>
  <results_first_submitted_qc>September 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2017</results_first_posted>
  <disposition_first_submitted>April 27, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 13, 2015</disposition_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>13 C oral breath test</keyword>
  <keyword>Type I and II Diabetes mellitus</keyword>
  <keyword>gastroparesis</keyword>
  <keyword>gut motility</keyword>
  <keyword>phase II</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>repeat dose</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>symptoms</keyword>
  <keyword>GSK962040</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 80 participants were enrolled and randomized from 03 May 2011 to 26 Feb 2013. The study was conducted at 22 centers, 1 center in Australia, 1 center in Sweden, 2 centers in Belgium, 4 centers in Canada, 5 Centers in United Kingdom and 9 centers in United States.</recruitment_details>
      <pre_assignment_details>Out of 80 participants randomized, 1 participant withdrew consent prior to dosing in GSK962040 50 milligram (mg) arm. Remaining 79 participants were included in &quot;All subject population&quot;</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="P2">
          <title>GSK962040 10 mg</title>
          <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="P3">
          <title>GSK962040 50 mg</title>
          <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="P4">
          <title>GSK962040 125 mg</title>
          <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="B2">
          <title>GSK962040 10 mg</title>
          <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="B3">
          <title>GSK962040 50 mg</title>
          <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="B4">
          <title>GSK962040 125 mg</title>
          <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="22"/>
            <count group_id="B5" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="14.23"/>
                    <measurement group_id="B2" value="54.0" spread="11.42"/>
                    <measurement group_id="B3" value="55.2" spread="12.17"/>
                    <measurement group_id="B4" value="51.4" spread="11.34"/>
                    <measurement group_id="B5" value="53.7" spread="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gastric Half Emptying Time (GEt1/2)</title>
        <description>Gastric half emptying time is the time taken for half the contents of the stomach to empty. Gastric emptying was measured using the 13C-oral breath test, which is a tracer method that utilizes 13C, a non-radioactive isotope. Basal breath samples were obtained after an overnight fast or otherwise after 4 hours of fasting following a light meal. On Day 1 and Day 28, participants were then dosed with GSK962040 and additional breath test samples were taken prior to administration of a 13C-labelled test meal. The test meal was consumed approximately 80 minutes(min) later. After consumption of the test meal, breath samples were collected at pre-specified time points over an approximately 4 hour period following the test meal. For the duration of the breath test, no food or drink were allowed. The 13C breath content was determined by isotope ratio mass spectrometry. GE t1/2 was determined by using the cumulative percentage of the administered dose of 13C excreted in breath over 4 hours.</description>
        <time_frame>Screening2/Baseline (Day -30 to -1) , Day 1, and Day 28</time_frame>
        <population>The â€˜All Subjects Populationâ€™ compromised of all participants who received at least one dose of study medication. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Gastric Half Emptying Time (GEt1/2)</title>
          <description>Gastric half emptying time is the time taken for half the contents of the stomach to empty. Gastric emptying was measured using the 13C-oral breath test, which is a tracer method that utilizes 13C, a non-radioactive isotope. Basal breath samples were obtained after an overnight fast or otherwise after 4 hours of fasting following a light meal. On Day 1 and Day 28, participants were then dosed with GSK962040 and additional breath test samples were taken prior to administration of a 13C-labelled test meal. The test meal was consumed approximately 80 minutes(min) later. After consumption of the test meal, breath samples were collected at pre-specified time points over an approximately 4 hour period following the test meal. For the duration of the breath test, no food or drink were allowed. The 13C breath content was determined by isotope ratio mass spectrometry. GE t1/2 was determined by using the cumulative percentage of the administered dose of 13C excreted in breath over 4 hours.</description>
          <population>The â€˜All Subjects Populationâ€™ compromised of all participants who received at least one dose of study medication. Only those participants available at specified time points were analyzed.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.2" spread="25.31"/>
                    <measurement group_id="O2" value="106.5" spread="23.42"/>
                    <measurement group_id="O3" value="118.2" spread="31.13"/>
                    <measurement group_id="O4" value="131.1" spread="32.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.1" spread="39.25"/>
                    <measurement group_id="O2" value="106.6" spread="27.07"/>
                    <measurement group_id="O3" value="104.8" spread="21.61"/>
                    <measurement group_id="O4" value="99.4" spread="33.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.8" spread="24.37"/>
                    <measurement group_id="O2" value="111.8" spread="32.23"/>
                    <measurement group_id="O3" value="107.9" spread="29.03"/>
                    <measurement group_id="O4" value="117.8" spread="44.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 10 mg versus Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.36</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.96</ci_lower_limit>
            <ci_upper_limit>15.24</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg versus Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.01</ci_lower_limit>
            <ci_upper_limit>6.40</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GSK962040 125 mg versus Placebo Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-25.65</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.99</ci_lower_limit>
            <ci_upper_limit>-8.32</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GSK962040 10 mg versus Placebo Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.74</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.06</ci_lower_limit>
            <ci_upper_limit>34.53</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GSK962040 50 mg vs Placebo Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.22</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.64</ci_lower_limit>
            <ci_upper_limit>23.08</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>GSK962040 125 mg versus Placebo Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.65</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.18</ci_lower_limit>
            <ci_upper_limit>24.47</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Day 28 versus Day 1 of the Placebo arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.92</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.73</ci_lower_limit>
            <ci_upper_limit>2.90</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 28 versus Day 1 of GSK962040 10 mg arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.69</ci_lower_limit>
            <ci_upper_limit>22.05</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Day 28 versus Day 1 of GSK962040 50 mg arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.11</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.13</ci_lower_limit>
            <ci_upper_limit>19.36</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Day 28 versus Day 1 of GSK962040 125 mg arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>19.39</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.47</ci_lower_limit>
            <ci_upper_limit>34.30</ci_upper_limit>
            <estimate_desc>The least square means were estimated using a mixed model fitting treatment, visit, treatment*visit and baseline gastric emptying half time as fixed effects, and participant as a random effect. Statistical analysis is reported using LS Means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Type 1 Diabetes, Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>-0.225</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.320</ci_lower_limit>
            <ci_upper_limit>-0.129</ci_upper_limit>
            <other_analysis_desc>Intercept estimate was 125.45 and between participant standard deviation was 21.63</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Type 1 Diabetes, Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>-0.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.171</ci_lower_limit>
            <ci_upper_limit>0.016</ci_upper_limit>
            <other_analysis_desc>Intercept estimate was 125.45 and between participant standard deviation was 21.63</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Type 2 Diabetes, Day 1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>-0.225</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.320</ci_lower_limit>
            <ci_upper_limit>-0.129</ci_upper_limit>
            <other_analysis_desc>Intercept estimate was 113.23 and between participant standard deviation was 21.63</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Type 2 Diabetes, Day 28</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>-0.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.171</ci_lower_limit>
            <ci_upper_limit>0.016</ci_upper_limit>
            <other_analysis_desc>Intercept estimate was 113.23 and between participant standard deviation was 21.63</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With On-treatment Adverse Events (AES) and Serious Adverse Events(SAEs)</title>
        <description>An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Data for on-treatment adverse events is reported.</description>
        <time_frame>Up to follow-up (5-10 days post last dose)</time_frame>
        <population>All Subjects population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With On-treatment Adverse Events (AES) and Serious Adverse Events(SAEs)</title>
          <description>An AE was defined as any untoward medical occurrence that occurred during the course of the trial after study treatment had started. An adverse event was therefore any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. Data for on-treatment adverse events is reported.</description>
          <population>All Subjects population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any on-treatment AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any on-treatment SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure(DBP) at Specified Time Points in Semi-supine Position</title>
        <description>Blood pressure measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The Baseline value was Day 1 Pre-Dose values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure(DBP) at Specified Time Points in Semi-supine Position</title>
          <description>Blood pressure measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The Baseline value was Day 1 Pre-Dose values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP Day 1 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="13.68"/>
                    <measurement group_id="O2" value="-1.8" spread="17.50"/>
                    <measurement group_id="O3" value="0.8" spread="18.07"/>
                    <measurement group_id="O4" value="-2.3" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Day 28 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="12.09"/>
                    <measurement group_id="O2" value="-1.1" spread="15.56"/>
                    <measurement group_id="O3" value="4.6" spread="16.47"/>
                    <measurement group_id="O4" value="-7.2" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Day 1 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="8.09"/>
                    <measurement group_id="O2" value="1.1" spread="7.45"/>
                    <measurement group_id="O3" value="-0.7" spread="8.50"/>
                    <measurement group_id="O4" value="-2.3" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Day 28 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.69"/>
                    <measurement group_id="O2" value="-0.8" spread="8.62"/>
                    <measurement group_id="O3" value="2.7" spread="6.33"/>
                    <measurement group_id="O4" value="-6.1" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate at Specified Time Points in Semi-supine Position</title>
        <description>Heart rate measurements were taken at pre-dose and 120 min (completion of meal) on Day 1 and Day 28. The Baseline value was Day 1 Pre-Dose values . Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline, Day 1, and Day 8</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate at Specified Time Points in Semi-supine Position</title>
          <description>Heart rate measurements were taken at pre-dose and 120 min (completion of meal) on Day 1 and Day 28. The Baseline value was Day 1 Pre-Dose values . Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Beats per minute (BPM)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate Day 1 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="7.60"/>
                    <measurement group_id="O2" value="-0.8" spread="6.64"/>
                    <measurement group_id="O3" value="-0.3" spread="8.39"/>
                    <measurement group_id="O4" value="2.1" spread="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 28 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="6.86"/>
                    <measurement group_id="O2" value="-1.5" spread="6.94"/>
                    <measurement group_id="O3" value="1.0" spread="9.09"/>
                    <measurement group_id="O4" value="0.7" spread="8.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiography Parameters (12-lead ECG)</title>
        <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 28. The Baseline value was the Day 1 pre-dose value. ECG parameters included PR interval, QRS duration, QT interval, QTcB, QTcF and RR interval.</description>
        <time_frame>Baseline, Day 1 and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiography Parameters (12-lead ECG)</title>
          <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 28. The Baseline value was the Day 1 pre-dose value. ECG parameters included PR interval, QRS duration, QT interval, QTcB, QTcF and RR interval.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval Day 1 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="10.40"/>
                    <measurement group_id="O2" value="3.2" spread="7.46"/>
                    <measurement group_id="O3" value="0.5" spread="13.03"/>
                    <measurement group_id="O4" value="-0.9" spread="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval Day 14 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="7.39"/>
                    <measurement group_id="O2" value="0.6" spread="7.87"/>
                    <measurement group_id="O3" value="-1.6" spread="11.29"/>
                    <measurement group_id="O4" value="-3.1" spread="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval Day 28 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="17.12"/>
                    <measurement group_id="O2" value="-7.1" spread="26.93"/>
                    <measurement group_id="O3" value="2.2" spread="18.32"/>
                    <measurement group_id="O4" value="-0.1" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval Day 28 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="14.28"/>
                    <measurement group_id="O2" value="0.5" spread="11.48"/>
                    <measurement group_id="O3" value="3.6" spread="16.71"/>
                    <measurement group_id="O4" value="-4.3" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration Day 1 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="5.18"/>
                    <measurement group_id="O2" value="-0.6" spread="4.16"/>
                    <measurement group_id="O3" value="0.1" spread="4.07"/>
                    <measurement group_id="O4" value="0.6" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration Day 14 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.26"/>
                    <measurement group_id="O2" value="-0.8" spread="4.33"/>
                    <measurement group_id="O3" value="-0.1" spread="3.57"/>
                    <measurement group_id="O4" value="-0.9" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration Day 28 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="4.93"/>
                    <measurement group_id="O2" value="1.1" spread="4.54"/>
                    <measurement group_id="O3" value="-0.3" spread="3.84"/>
                    <measurement group_id="O4" value="1.0" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration Day 28 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="4.29"/>
                    <measurement group_id="O2" value="0.6" spread="3.98"/>
                    <measurement group_id="O3" value="-0.3" spread="4.96"/>
                    <measurement group_id="O4" value="0.0" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval Day 1 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="12.30"/>
                    <measurement group_id="O2" value="-0.2" spread="17.45"/>
                    <measurement group_id="O3" value="-3.8" spread="13.16"/>
                    <measurement group_id="O4" value="1.6" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval Day 14 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="18.52"/>
                    <measurement group_id="O2" value="-9.6" spread="19.11"/>
                    <measurement group_id="O3" value="-10.7" spread="25.58"/>
                    <measurement group_id="O4" value="-9.6" spread="19.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval Day 28 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="21.83"/>
                    <measurement group_id="O2" value="-5.0" spread="21.36"/>
                    <measurement group_id="O3" value="-2.0" spread="23.20"/>
                    <measurement group_id="O4" value="-3.0" spread="20.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval Day 28 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="16.37"/>
                    <measurement group_id="O2" value="-2.8" spread="22.18"/>
                    <measurement group_id="O3" value="-1.3" spread="26.49"/>
                    <measurement group_id="O4" value="-4.5" spread="21.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Day 1 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.84" spread="13.906"/>
                    <measurement group_id="O2" value="-1.94" spread="13.721"/>
                    <measurement group_id="O3" value="-2.45" spread="13.447"/>
                    <measurement group_id="O4" value="-0.12" spread="15.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Day 14 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23" spread="11.503"/>
                    <measurement group_id="O2" value="-2.97" spread="12.075"/>
                    <measurement group_id="O3" value="-2.68" spread="18.410"/>
                    <measurement group_id="O4" value="-1.42" spread="16.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Day 28 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.85" spread="20.907"/>
                    <measurement group_id="O2" value="2.71" spread="9.741"/>
                    <measurement group_id="O3" value="1.31" spread="18.419"/>
                    <measurement group_id="O4" value="-0.20" spread="15.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Day 28 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="24.246"/>
                    <measurement group_id="O2" value="1.86" spread="14.682"/>
                    <measurement group_id="O3" value="-0.16" spread="17.208"/>
                    <measurement group_id="O4" value="-0.88" spread="15.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Day 1 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.52" spread="12.089"/>
                    <measurement group_id="O2" value="-1.26" spread="14.709"/>
                    <measurement group_id="O3" value="-2.84" spread="11.080"/>
                    <measurement group_id="O4" value="0.72" spread="12.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Day 14 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="11.942"/>
                    <measurement group_id="O2" value="-5.57" spread="12.599"/>
                    <measurement group_id="O3" value="-5.91" spread="19.109"/>
                    <measurement group_id="O4" value="-4.37" spread="13.314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Day 28 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="18.782"/>
                    <measurement group_id="O2" value="0.04" spread="12.835"/>
                    <measurement group_id="O3" value="0.96" spread="15.942"/>
                    <measurement group_id="O4" value="-1.21" spread="12.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Day 28 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="20.473"/>
                    <measurement group_id="O2" value="-0.24" spread="14.344"/>
                    <measurement group_id="O3" value="-0.64" spread="16.857"/>
                    <measurement group_id="O4" value="-2.17" spread="12.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR interval Day 1 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.82" spread="56.084"/>
                    <measurement group_id="O2" value="7.26" spread="44.025"/>
                    <measurement group_id="O3" value="-3.26" spread="68.824"/>
                    <measurement group_id="O4" value="8.74" spread="81.926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR interval Day 14 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.61" spread="76.965"/>
                    <measurement group_id="O2" value="-33.95" spread="75.539"/>
                    <measurement group_id="O3" value="-42.92" spread="90.333"/>
                    <measurement group_id="O4" value="-35.25" spread="102.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR interval Day 28 pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.15" spread="109.227"/>
                    <measurement group_id="O2" value="-31.14" spread="75.740"/>
                    <measurement group_id="O3" value="-3.31" spread="99.049"/>
                    <measurement group_id="O4" value="-11.51" spread="108.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR interval Day 28 1.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.96" spread="76.906"/>
                    <measurement group_id="O2" value="-23.69" spread="96.568"/>
                    <measurement group_id="O3" value="-4.08" spread="114.019"/>
                    <measurement group_id="O4" value="-15.60" spread="108.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Outside the Normal Range for SBP and DBP</title>
        <description>Blood pressure measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The clinical concern range (CCR) for SBP was greater than (&lt;) 85 and less than (&gt;) 160 and for DBP the range was &lt;45 and &gt;100. Data for semi-supine position has been presented. Baseline was Screening2/Baseline values.</description>
        <time_frame>Screening2/Baseline (Day -30 to -1), Day 1 and 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Outside the Normal Range for SBP and DBP</title>
          <description>Blood pressure measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The clinical concern range (CCR) for SBP was greater than (&lt;) 85 and less than (&gt;) 160 and for DBP the range was &lt;45 and &gt;100. Data for semi-supine position has been presented. Baseline was Screening2/Baseline values.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP Screening 3.5 hours &lt; CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Screening 3.5 hours&gt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Day 1 3.5 hours&lt; CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Day 1 3.5 hours&gt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Day 28 3.5 hours&lt; CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Day 28 3.5 hours&gt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Screening 3.5 hours&lt; CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Screening 3.5 hours&gt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Day 1 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Day 1 3.5 hours - 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Day 28 3.5 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Day 28 3.5 hours - 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Outside the Normal Range for Heart Rate</title>
        <description>Heart rate measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The CCR for heart rate was Increase or decrease by less than or equal to (&gt;=) 15 and &gt;= 30. Data for semi-supine position has been presented. Baseline was Screening2/Baseline values.</description>
        <time_frame>Screening2/Baseline (Day -30 to -1), Day 1 and 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Outside the Normal Range for Heart Rate</title>
          <description>Heart rate measurements were taken at pre-dose and at 120 min (completion of meal) on Day 1 and Day 28. The CCR for heart rate was Increase or decrease by less than or equal to (&gt;=) 15 and &gt;= 30. Data for semi-supine position has been presented. Baseline was Screening2/Baseline values.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate Screening 3.5 hours &lt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Screening 3.5 hours &gt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 1 3.5 hours &lt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 1 3.5 hours &gt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 28 3.5 hours&lt;CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 28 3.5 hours&gt; CCR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Outside the Normal Range for 12-lead ECG</title>
        <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 28. The CCR for ECG parameters were: PR interval (&lt;110 and &gt;220), QRS interval (&lt;75 and &gt;110), Absolute QTc interval (&gt;450 to =&lt; 480) respectively. Baseline was the pre-dose reading for Day 1. Data for abnormal- clinically significant (ACS) and abnormal- not clinically significant (ANCS) has been presented.</description>
        <time_frame>Baseline (Day 1 pre-dose), Day 1, Day 14 and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Outside the Normal Range for 12-lead ECG</title>
          <description>ECG measurements were taken at pre-dose and 0 min (completion of meal) on Day 1 and Day 28. The CCR for ECG parameters were: PR interval (&lt;110 and &gt;220), QRS interval (&lt;75 and &gt;110), Absolute QTc interval (&gt;450 to =&lt; 480) respectively. Baseline was the pre-dose reading for Day 1. Data for abnormal- clinically significant (ACS) and abnormal- not clinically significant (ANCS) has been presented.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 pre-dose ANCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 pre-dose ACS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1.5 hour ANCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1.5 hour ACS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 pre-dose ANCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14 pre-dose ACS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 pre-dose ANCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 pre-dose ACS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 1.5 hour ANCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 1.5 hour ACS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Chemistry: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Gamma Glutamyl Transferase, Creatine Kinase, Lactate Dehydrogenase</title>
        <description>Alkaline phosphatase, alanine amino transferase, aspartate amino transferase, gamma glutamyl transferase, creatine kinase, lactate dehydrogenase measurements were taken at Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Chemistry: Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Gamma Glutamyl Transferase, Creatine Kinase, Lactate Dehydrogenase</title>
          <description>Alkaline phosphatase, alanine amino transferase, aspartate amino transferase, gamma glutamyl transferase, creatine kinase, lactate dehydrogenase measurements were taken at Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline Phosphatase Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="7.54"/>
                    <measurement group_id="O2" value="4.3" spread="7.20"/>
                    <measurement group_id="O3" value="4.0" spread="9.27"/>
                    <measurement group_id="O4" value="-1.1" spread="23.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="8.63"/>
                    <measurement group_id="O2" value="5.0" spread="7.79"/>
                    <measurement group_id="O3" value="2.8" spread="10.58"/>
                    <measurement group_id="O4" value="-1.3" spread="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="9.17"/>
                    <measurement group_id="O2" value="5.0" spread="8.16"/>
                    <measurement group_id="O3" value="0.7" spread="8.70"/>
                    <measurement group_id="O4" value="-4.3" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="15.25"/>
                    <measurement group_id="O2" value="3.9" spread="9.19"/>
                    <measurement group_id="O3" value="1.7" spread="11.39"/>
                    <measurement group_id="O4" value="-1.7" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="14.05"/>
                    <measurement group_id="O2" value="3.1" spread="7.17"/>
                    <measurement group_id="O3" value="-2.5" spread="14.66"/>
                    <measurement group_id="O4" value="-1.7" spread="25.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.28"/>
                    <measurement group_id="O2" value="2.6" spread="7.31"/>
                    <measurement group_id="O3" value="2.8" spread="10.88"/>
                    <measurement group_id="O4" value="-1.1" spread="16.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="7.86"/>
                    <measurement group_id="O2" value="2.5" spread="6.60"/>
                    <measurement group_id="O3" value="-1.2" spread="4.93"/>
                    <measurement group_id="O4" value="-1.1" spread="17.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="7.32"/>
                    <measurement group_id="O2" value="2.9" spread="6.99"/>
                    <measurement group_id="O3" value="-1.0" spread="6.94"/>
                    <measurement group_id="O4" value="-3.2" spread="15.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.74"/>
                    <measurement group_id="O2" value="0.3" spread="6.09"/>
                    <measurement group_id="O3" value="-0.1" spread="5.89"/>
                    <measurement group_id="O4" value="-2.9" spread="14.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="5.39"/>
                    <measurement group_id="O2" value="1.1" spread="6.22"/>
                    <measurement group_id="O3" value="-1.2" spread="6.88"/>
                    <measurement group_id="O4" value="-4.0" spread="13.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="5.68"/>
                    <measurement group_id="O2" value="0.1" spread="6.73"/>
                    <measurement group_id="O3" value="-1.9" spread="9.90"/>
                    <measurement group_id="O4" value="1.6" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="9.08"/>
                    <measurement group_id="O2" value="1.2" spread="8.27"/>
                    <measurement group_id="O3" value="-2.7" spread="10.67"/>
                    <measurement group_id="O4" value="2.8" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="5.50"/>
                    <measurement group_id="O2" value="-1.1" spread="6.94"/>
                    <measurement group_id="O3" value="-2.8" spread="11.35"/>
                    <measurement group_id="O4" value="1.0" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="6.80"/>
                    <measurement group_id="O2" value="-0.3" spread="6.78"/>
                    <measurement group_id="O3" value="-1.2" spread="9.55"/>
                    <measurement group_id="O4" value="1.6" spread="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="6.63"/>
                    <measurement group_id="O2" value="0.4" spread="5.41"/>
                    <measurement group_id="O3" value="-2.7" spread="9.13"/>
                    <measurement group_id="O4" value="0.5" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.43"/>
                    <measurement group_id="O2" value="1.8" spread="4.35"/>
                    <measurement group_id="O3" value="1.6" spread="6.26"/>
                    <measurement group_id="O4" value="2.4" spread="8.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.88"/>
                    <measurement group_id="O2" value="0.5" spread="4.16"/>
                    <measurement group_id="O3" value="1.8" spread="7.09"/>
                    <measurement group_id="O4" value="1.2" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="4.57"/>
                    <measurement group_id="O2" value="0.4" spread="3.10"/>
                    <measurement group_id="O3" value="2.1" spread="6.55"/>
                    <measurement group_id="O4" value="1.5" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="5.11"/>
                    <measurement group_id="O2" value="-1.3" spread="5.00"/>
                    <measurement group_id="O3" value="1.8" spread="3.52"/>
                    <measurement group_id="O4" value="2.6" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="5.44"/>
                    <measurement group_id="O2" value="0.5" spread="5.51"/>
                    <measurement group_id="O3" value="0.3" spread="4.37"/>
                    <measurement group_id="O4" value="4.2" spread="16.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="61.05"/>
                    <measurement group_id="O2" value="41.9" spread="74.29"/>
                    <measurement group_id="O3" value="42.0" spread="103.49"/>
                    <measurement group_id="O4" value="0.2" spread="42.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="38.69"/>
                    <measurement group_id="O2" value="8.6" spread="31.10"/>
                    <measurement group_id="O3" value="-5.8" spread="42.29"/>
                    <measurement group_id="O4" value="-16.2" spread="40.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Chemistry: Direct Bilirubin, Total Bilirubin, Creatinine, Uric Acid</title>
        <description>Direct Bilirubin, Total Bilirubin, Creatinine, Uric acid measurements were taken at Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Chemistry: Direct Bilirubin, Total Bilirubin, Creatinine, Uric Acid</title>
          <description>Direct Bilirubin, Total Bilirubin, Creatinine, Uric acid measurements were taken at Baseline (Day 1 pre-dose), Day 5, 10, 14, 21 and 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Unit moles per litre (UMOL/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.75"/>
                    <measurement group_id="O2" value="-0.2" spread="1.27"/>
                    <measurement group_id="O3" value="-0.1" spread="0.62"/>
                    <measurement group_id="O4" value="-0.0" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.75"/>
                    <measurement group_id="O2" value="0.0" spread="1.65"/>
                    <measurement group_id="O3" value="-0.1" spread="0.75"/>
                    <measurement group_id="O4" value="-0.0" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.57"/>
                    <measurement group_id="O2" value="0.1" spread="1.19"/>
                    <measurement group_id="O3" value="-0.2" spread="0.70"/>
                    <measurement group_id="O4" value="-0.0" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.75"/>
                    <measurement group_id="O2" value="0.2" spread="1.35"/>
                    <measurement group_id="O3" value="-0.2" spread="0.90"/>
                    <measurement group_id="O4" value="0.1" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.74"/>
                    <measurement group_id="O2" value="0.3" spread="1.57"/>
                    <measurement group_id="O3" value="0.1" spread="0.98"/>
                    <measurement group_id="O4" value="-0.1" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.43"/>
                    <measurement group_id="O2" value="0.4" spread="2.71"/>
                    <measurement group_id="O3" value="-2.6" spread="3.41"/>
                    <measurement group_id="O4" value="-0.5" spread="3.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.25"/>
                    <measurement group_id="O2" value="-0.1" spread="3.13"/>
                    <measurement group_id="O3" value="-1.8" spread="4.83"/>
                    <measurement group_id="O4" value="-0.4" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.41"/>
                    <measurement group_id="O2" value="0.2" spread="2.99"/>
                    <measurement group_id="O3" value="-2.1" spread="3.15"/>
                    <measurement group_id="O4" value="-0.3" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.53"/>
                    <measurement group_id="O2" value="0.4" spread="3.72"/>
                    <measurement group_id="O3" value="-1.2" spread="3.49"/>
                    <measurement group_id="O4" value="-0.2" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.87"/>
                    <measurement group_id="O2" value="1.2" spread="3.45"/>
                    <measurement group_id="O3" value="-0.6" spread="2.71"/>
                    <measurement group_id="O4" value="-0.9" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.91" spread="6.156"/>
                    <measurement group_id="O2" value="0.51" spread="7.415"/>
                    <measurement group_id="O3" value="9.42" spread="17.103"/>
                    <measurement group_id="O4" value="9.80" spread="11.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.61" spread="39.359"/>
                    <measurement group_id="O2" value="3.56" spread="32.183"/>
                    <measurement group_id="O3" value="8.62" spread="25.412"/>
                    <measurement group_id="O4" value="18.29" spread="39.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Chemistry : Albumin, Total Protein</title>
        <description>Albumin, Total Protein measurements were taken at Baseline (Day 1 pre-dose), and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Chemistry : Albumin, Total Protein</title>
          <description>Albumin, Total Protein measurements were taken at Baseline (Day 1 pre-dose), and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="2.335"/>
                    <measurement group_id="O2" value="0.49" spread="2.040"/>
                    <measurement group_id="O3" value="0.11" spread="1.323"/>
                    <measurement group_id="O4" value="-0.66" spread="2.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="3.79"/>
                    <measurement group_id="O2" value="0.7" spread="2.94"/>
                    <measurement group_id="O3" value="1.0" spread="2.68"/>
                    <measurement group_id="O4" value="-0.5" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Clinical Chemistry : Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon Dioxide Content/Bicarbonate</title>
        <description>Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon dioxide content/Bicarbonate measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Clinical Chemistry : Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon Dioxide Content/Bicarbonate</title>
          <description>Calcium, Chloride, Glucose, Potassium, Sodium, Urea/BUN, Carbon dioxide content/Bicarbonate measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Millimoles per liter (MMOL/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.1067"/>
                    <measurement group_id="O2" value="-0.017" spread="0.0764"/>
                    <measurement group_id="O3" value="0.027" spread="0.0666"/>
                    <measurement group_id="O4" value="-0.031" spread="0.1323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="3.754"/>
                    <measurement group_id="O2" value="-0.93" spread="3.137"/>
                    <measurement group_id="O3" value="-0.94" spread="2.578"/>
                    <measurement group_id="O4" value="0.15" spread="2.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="4.343"/>
                    <measurement group_id="O2" value="0.24" spread="3.638"/>
                    <measurement group_id="O3" value="0.66" spread="6.790"/>
                    <measurement group_id="O4" value="-0.25" spread="2.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="0.3564"/>
                    <measurement group_id="O2" value="0.094" spread="0.6002"/>
                    <measurement group_id="O3" value="-0.111" spread="0.5132"/>
                    <measurement group_id="O4" value="-0.068" spread="0.3999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="3.203"/>
                    <measurement group_id="O2" value="-0.41" spread="2.303"/>
                    <measurement group_id="O3" value="-0.56" spread="2.833"/>
                    <measurement group_id="O4" value="0.00" spread="1.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="2.021"/>
                    <measurement group_id="O2" value="-0.31" spread="1.778"/>
                    <measurement group_id="O3" value="-0.04" spread="1.942"/>
                    <measurement group_id="O4" value="0.26" spread="2.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide content/Bicarbonate Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="1.843"/>
                    <measurement group_id="O2" value="-0.79" spread="2.286"/>
                    <measurement group_id="O3" value="1.17" spread="2.526"/>
                    <measurement group_id="O4" value="-0.08" spread="2.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematology Parameters : Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet Count, White Blood Cell Count</title>
        <description>Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet count, White Blood cell count measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematology Parameters : Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet Count, White Blood Cell Count</title>
          <description>Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (Total ANC - Total Absolute Neutrophil Count), Platelet count, White Blood cell count measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Giga (10^9) cells per liter (GI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0066" spread="0.03852"/>
                    <measurement group_id="O2" value="-0.0388" spread="0.09539"/>
                    <measurement group_id="O3" value="-0.0322" spread="0.07998"/>
                    <measurement group_id="O4" value="0.1072" spread="0.43592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0167" spread="0.07137"/>
                    <measurement group_id="O2" value="0.0431" spread="0.11412"/>
                    <measurement group_id="O3" value="-0.0040" spread="0.18975"/>
                    <measurement group_id="O4" value="0.1173" spread="0.41877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0485" spread="0.44972"/>
                    <measurement group_id="O2" value="-0.0561" spread="0.45151"/>
                    <measurement group_id="O3" value="0.1887" spread="0.31662"/>
                    <measurement group_id="O4" value="-0.0099" spread="0.34075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0327" spread="0.16668"/>
                    <measurement group_id="O2" value="-0.0530" spread="0.09965"/>
                    <measurement group_id="O3" value="-0.0097" spread="0.17272"/>
                    <measurement group_id="O4" value="-0.0298" spread="0.10623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1380" spread="0.78256"/>
                    <measurement group_id="O2" value="0.2159" spread="1.28307"/>
                    <measurement group_id="O3" value="0.2949" spread="1.20093"/>
                    <measurement group_id="O4" value="-0.7640" spread="1.97899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="32.76"/>
                    <measurement group_id="O2" value="1.5" spread="35.37"/>
                    <measurement group_id="O3" value="0.6" spread="28.87"/>
                    <measurement group_id="O4" value="-2.0" spread="21.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood cell count Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.144" spread="1.0951"/>
                    <measurement group_id="O2" value="0.225" spread="1.4369"/>
                    <measurement group_id="O3" value="0.428" spread="1.0110"/>
                    <measurement group_id="O4" value="-0.730" spread="2.0794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematology Parameters : Hematocrit</title>
        <description>Hematocrit measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematology Parameters : Hematocrit</title>
          <description>Hematocrit measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0025" spread="0.01692"/>
                    <measurement group_id="O2" value="0.0021" spread="0.01053"/>
                    <measurement group_id="O3" value="0.0019" spread="0.01508"/>
                    <measurement group_id="O4" value="-0.0059" spread="0.01637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Hemoglobin</title>
        <description>Mean Corpuscle Hemoglobin measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Hemoglobin</title>
          <description>Mean Corpuscle Hemoglobin measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Picograms (Pg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.521"/>
                    <measurement group_id="O2" value="0.15" spread="0.454"/>
                    <measurement group_id="O3" value="-0.15" spread="0.667"/>
                    <measurement group_id="O4" value="-0.14" spread="0.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematology Parameters : Hemoglobin, Mean Corpuscle Hemoglobin Concentration</title>
        <description>Hemoglobin, Mean Corpuscle Hemoglobin concentration measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematology Parameters : Hemoglobin, Mean Corpuscle Hemoglobin Concentration</title>
          <description>Hemoglobin, Mean Corpuscle Hemoglobin concentration measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="5.36"/>
                    <measurement group_id="O2" value="1.1" spread="4.63"/>
                    <measurement group_id="O3" value="-0.2" spread="5.46"/>
                    <measurement group_id="O4" value="-2.7" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin concentration Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="6.20"/>
                    <measurement group_id="O2" value="1.6" spread="4.92"/>
                    <measurement group_id="O3" value="-2.8" spread="6.53"/>
                    <measurement group_id="O4" value="-1.9" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Volume</title>
        <description>Mean Corpuscle Volume measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematology Parameters : Mean Corpuscle Volume</title>
          <description>Mean Corpuscle Volume measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Femtoliters (FL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.952"/>
                    <measurement group_id="O2" value="-0.24" spread="1.163"/>
                    <measurement group_id="O3" value="0.43" spread="1.514"/>
                    <measurement group_id="O4" value="0.13" spread="1.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematology Parameters : Red Blood Cell Count, Reticulocytes</title>
        <description>Red Blood Cell count, Reticulocytes measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline (Day 1 pre-dose) and Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematology Parameters : Red Blood Cell Count, Reticulocytes</title>
          <description>Red Blood Cell count, Reticulocytes measurements were taken at Baseline (Day 1 pre-dose) and Day 28. The Baseline value was the Day 1 pre-dose value. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Tera (10^12) cells per liter (TI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Blood Cell count Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.2015"/>
                    <measurement group_id="O2" value="0.035" spread="0.1399"/>
                    <measurement group_id="O3" value="0.003" spread="0.1597"/>
                    <measurement group_id="O4" value="-0.072" spread="0.1660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0080" spread="0.02949"/>
                    <measurement group_id="O2" value="-0.0051" spread="0.01418"/>
                    <measurement group_id="O3" value="0.0070" spread="0.01919"/>
                    <measurement group_id="O4" value="-0.0050" spread="0.01937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration AUC(0-t) at Specified Time Points</title>
        <description>AUC(0-t) was derived from GSK962040 plasma concentration-time data. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.Only participants who received GSK962040 drug were analyzed.</description>
        <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
        <population>The â€˜Pharmacokinetic (PK) Population' was defined as participants in the â€˜All subjectsâ€™ population for whom a PK sample was obtained and analyzed. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration AUC(0-t) at Specified Time Points</title>
          <description>AUC(0-t) was derived from GSK962040 plasma concentration-time data. AUC was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations.Only participants who received GSK962040 drug were analyzed.</description>
          <population>The â€˜Pharmacokinetic (PK) Population' was defined as participants in the â€˜All subjectsâ€™ population for whom a PK sample was obtained and analyzed. Only those participants available at specified time points were analyzed.</population>
          <units>Nanograms.hour/milliliter (ng.h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="854.9" spread="36.6"/>
                    <measurement group_id="O2" value="4083.1" spread="23.6"/>
                    <measurement group_id="O3" value="12911.9" spread="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1908.1" spread="46.1"/>
                    <measurement group_id="O2" value="7347.2" spread="24.3"/>
                    <measurement group_id="O3" value="22173.3" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) at Specified Time Points</title>
        <description>Cmax is defined as the maximum observed drug concentration after administration. Cmax was determined directly from the raw concentration-time data. Samples were collected at the following times: Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose.</description>
        <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
        <population>PK population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) at Specified Time Points</title>
          <description>Cmax is defined as the maximum observed drug concentration after administration. Cmax was determined directly from the raw concentration-time data. Samples were collected at the following times: Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose.</description>
          <population>PK population. Only those participants available at specified time points were analyzed.</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.21" spread="54.7"/>
                    <measurement group_id="O2" value="385.73" spread="27.6"/>
                    <measurement group_id="O3" value="1239.62" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131.71" spread="52.9"/>
                    <measurement group_id="O2" value="530.97" spread="34.0"/>
                    <measurement group_id="O3" value="1703.29" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Occurrence of Cmax (Tmax) at Specified Time Points</title>
        <description>Tmax is defined as the time to reach the observed maximum concentration. Samples were collected at the following times: Tmax was determined directly from the raw concentration-time data. Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose.</description>
        <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
        <population>PK population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Cmax (Tmax) at Specified Time Points</title>
          <description>Tmax is defined as the time to reach the observed maximum concentration. Samples were collected at the following times: Tmax was determined directly from the raw concentration-time data. Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose.</description>
          <population>PK population. Only those participants available at specified time points were analyzed.</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.174" spread="0.9066"/>
                    <measurement group_id="O2" value="2.238" spread="1.0697"/>
                    <measurement group_id="O3" value="2.092" spread="0.8419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.189" spread="1.3976"/>
                    <measurement group_id="O2" value="2.168" spread="0.7224"/>
                    <measurement group_id="O3" value="2.026" spread="1.2038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ct) at Specified Time Points</title>
        <description>Analysis of pre-dose (trough) concentration at the end of the dosing interval (Ct) was planned to be performed from the samples collected at Pre -dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28.</description>
        <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
        <population>PK population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ct) at Specified Time Points</title>
          <description>Analysis of pre-dose (trough) concentration at the end of the dosing interval (Ct) was planned to be performed from the samples collected at Pre -dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28.</description>
          <population>PK population.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.73" spread="34.853"/>
                    <measurement group_id="O2" value="214.26" spread="146.572"/>
                    <measurement group_id="O3" value="537.23" spread="290.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.60" spread="32.830"/>
                    <measurement group_id="O2" value="205.03" spread="84.251"/>
                    <measurement group_id="O3" value="597.39" spread="321.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance Following Oral Dosing (CL/F) at Specified Time Points</title>
        <description>CL/F was calculated as dose/AUC. The parameter was planned to be analyzed from samples collected at Pre -dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however the data for this outcome measure was not collected.</description>
        <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
        <population>PK Population. The data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance Following Oral Dosing (CL/F) at Specified Time Points</title>
          <description>CL/F was calculated as dose/AUC. The parameter was planned to be analyzed from samples collected at Pre -dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however the data for this outcome measure was not collected.</description>
          <population>PK Population. The data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (V/F) at Specified Time Points</title>
        <description>The apparent volume of distribution V/F = CL/F Ã— MRT, where MRT is the mean residence time. The parameter was planned to be analyzed using samples collected at Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however, the data for this outcome measure was not collected.</description>
        <time_frame>Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28</time_frame>
        <population>PK Population. The data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (V/F) at Specified Time Points</title>
          <description>The apparent volume of distribution V/F = CL/F Ã— MRT, where MRT is the mean residence time. The parameter was planned to be analyzed using samples collected at Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however, the data for this outcome measure was not collected.</description>
          <population>PK Population. The data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-life (t1/2) at Specified Time Points</title>
        <description>This outcome measure was not analyzed in results.</description>
        <time_frame>The parameter was planned to be analyzed using samples collected at Pre-dose and 1.5, 2.5, 3.5, 4.5, and 5.5 hours post dose on Day 1 and 28, however, the data for this outcome measure was not collected.</time_frame>
        <population>PK Population. The data for this outcome measure was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-life (t1/2) at Specified Time Points</title>
          <description>This outcome measure was not analyzed in results.</description>
          <population>PK Population. The data for this outcome measure was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Bowel Movement After First Dose</title>
        <description>The time to first bowel movement was calculated as the time of the first bowel movement after the first dose in hours (floored) for each participant. If a participant had fewer than 5 days worth of data then the daily mean for that week was set to missing for the following two parameters: Bowel Movement Count and Stool Consistency. Seventeen participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics of time to first bowel movement.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Bowel Movement After First Dose</title>
          <description>The time to first bowel movement was calculated as the time of the first bowel movement after the first dose in hours (floored) for each participant. If a participant had fewer than 5 days worth of data then the daily mean for that week was set to missing for the following two parameters: Bowel Movement Count and Stool Consistency. Seventeen participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics of time to first bowel movement.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.94" spread="25.044"/>
                    <measurement group_id="O2" value="53.98" spread="67.901"/>
                    <measurement group_id="O3" value="17.52" spread="19.286"/>
                    <measurement group_id="O4" value="15.73" spread="15.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Bowel Movement Frequency</title>
        <description>Daily bowel movement frequency analyzed number of times passed stools in 24 hours of duration. Following dosing with study medication, stool monitoring was performed up to Day 28. Seventeen participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics.</description>
        <time_frame>Up to Week 4 (Day 28)</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Bowel Movement Frequency</title>
          <description>Daily bowel movement frequency analyzed number of times passed stools in 24 hours of duration. Following dosing with study medication, stool monitoring was performed up to Day 28. Seventeen participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Bowel movements/24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.872"/>
                    <measurement group_id="O2" value="1.33" spread="0.812"/>
                    <measurement group_id="O3" value="1.50" spread="0.943"/>
                    <measurement group_id="O4" value="1.39" spread="0.729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="3.473"/>
                    <measurement group_id="O2" value="1.59" spread="0.948"/>
                    <measurement group_id="O3" value="1.55" spread="1.012"/>
                    <measurement group_id="O4" value="1.45" spread="0.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="3.269"/>
                    <measurement group_id="O2" value="1.44" spread="0.830"/>
                    <measurement group_id="O3" value="1.77" spread="1.172"/>
                    <measurement group_id="O4" value="1.38" spread="0.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="3.432"/>
                    <measurement group_id="O2" value="1.54" spread="0.841"/>
                    <measurement group_id="O3" value="1.68" spread="1.049"/>
                    <measurement group_id="O4" value="1.37" spread="0.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Average Stool Consistency</title>
        <description>Stool consistency was determined on a scale of 1 to 5 (1 = Very hard, 2 = Hard, 3 = Formed, 4 = Loose, 5 = Watery). Following dosing with study medication, stool monitoring was performed up to Day 28. Participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics.</description>
        <time_frame>Up to Week 4 (Day 28)</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Average Stool Consistency</title>
          <description>Stool consistency was determined on a scale of 1 to 5 (1 = Very hard, 2 = Hard, 3 = Formed, 4 = Loose, 5 = Watery). Following dosing with study medication, stool monitoring was performed up to Day 28. Participants who entered their time of first instance of bowel movement before taking first dose were excluded from the summary statistics.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Bowel Movements/ 24 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.91" spread="0.817"/>
                    <measurement group_id="O2" value="3.24" spread="0.524"/>
                    <measurement group_id="O3" value="2.80" spread="0.815"/>
                    <measurement group_id="O4" value="3.71" spread="0.874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="0.730"/>
                    <measurement group_id="O2" value="2.81" spread="0.673"/>
                    <measurement group_id="O3" value="3.05" spread="0.798"/>
                    <measurement group_id="O4" value="3.29" spread="0.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="0.517"/>
                    <measurement group_id="O2" value="2.87" spread="0.889"/>
                    <measurement group_id="O3" value="2.99" spread="0.558"/>
                    <measurement group_id="O4" value="3.26" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="0.528"/>
                    <measurement group_id="O2" value="2.96" spread="0.625"/>
                    <measurement group_id="O3" value="2.98" spread="0.502"/>
                    <measurement group_id="O4" value="3.37" spread="0.569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Upper Gastrointestinal (GI) Symptoms as Assessed by Total Gastrointestinal Cardinal Symptom Index â€“ Daily Diary (GCSIâ€“DD)</title>
        <description>GCSIâ€“DD was measured on a 6-point scale. The Total GCSI-DD score was the mean of the following three subscales: Nausea/Vomiting Subscale = mean (nausea, retching, vomiting), Fullness/Early Satiety Subscale = mean (feeling excessively full after meals, not able to finish a normal-sized meal, stomach fullness, loss of appetite), Bloating Subscale = mean (bloating, stomach or belly visibly larger). Each subscale was scored on a severity scale of 0 (none) to 5 (very severe), with lower scores representing less symptom severity. The change from Baseline to each study week in average score was derived and if it improved by 1 point or more, that participant was defined as â€œresponderâ€ for that symptom and on that particular week. Baseline was Screening2/Baseline values (Day -30 to -1). Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Up to 14 days post last dose (Day 28)</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Upper Gastrointestinal (GI) Symptoms as Assessed by Total Gastrointestinal Cardinal Symptom Index â€“ Daily Diary (GCSIâ€“DD)</title>
          <description>GCSIâ€“DD was measured on a 6-point scale. The Total GCSI-DD score was the mean of the following three subscales: Nausea/Vomiting Subscale = mean (nausea, retching, vomiting), Fullness/Early Satiety Subscale = mean (feeling excessively full after meals, not able to finish a normal-sized meal, stomach fullness, loss of appetite), Bloating Subscale = mean (bloating, stomach or belly visibly larger). Each subscale was scored on a severity scale of 0 (none) to 5 (very severe), with lower scores representing less symptom severity. The change from Baseline to each study week in average score was derived and if it improved by 1 point or more, that participant was defined as â€œresponderâ€ for that symptom and on that particular week. Baseline was Screening2/Baseline values (Day -30 to -1). Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.645"/>
                    <measurement group_id="O2" value="-0.46" spread="0.676"/>
                    <measurement group_id="O3" value="-0.58" spread="0.379"/>
                    <measurement group_id="O4" value="-0.57" spread="0.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.728"/>
                    <measurement group_id="O2" value="-1.04" spread="1.062"/>
                    <measurement group_id="O3" value="-1.21" spread="0.663"/>
                    <measurement group_id="O4" value="-0.72" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.770"/>
                    <measurement group_id="O2" value="-1.29" spread="0.936"/>
                    <measurement group_id="O3" value="-1.16" spread="0.745"/>
                    <measurement group_id="O4" value="-0.77" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="1.001"/>
                    <measurement group_id="O2" value="-1.32" spread="0.980"/>
                    <measurement group_id="O3" value="-1.12" spread="0.670"/>
                    <measurement group_id="O4" value="-0.82" spread="0.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.87" spread="0.951"/>
                    <measurement group_id="O2" value="-1.19" spread="0.906"/>
                    <measurement group_id="O3" value="-1.07" spread="0.738"/>
                    <measurement group_id="O4" value="-0.74" spread="0.728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.943"/>
                    <measurement group_id="O2" value="-0.96" spread="1.000"/>
                    <measurement group_id="O3" value="-0.86" spread="0.632"/>
                    <measurement group_id="O4" value="-0.59" spread="0.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)</title>
        <description>WMC is an ingestible telemetric capsule which measures pH, pressure and temperature to assess total gastric emptying time, small and large bowel transit time, colonic transit time, and whole gut transit time. The WMC was ingested immediately following the standard test meal for the oral breath test. Data was collected on a data logger, which was worn on a belt clip. The WMC passed naturally in the participantâ€™s stools between 2 and 5 days after ingestion. The parameters Whole bowel transit time, 100 % gastric emptying time (truncated at 240 minutes), small bowel transit time, colonic transit time were analyzed. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
        <time_frame>Baseline(Screening i.e., Day -30 to -1), Day 1 and 28</time_frame>
        <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK962040 10 mg</title>
            <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O3">
            <title>GSK962040 50 mg</title>
            <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
          <group group_id="O4">
            <title>GSK962040 125 mg</title>
            <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Whole Bowel Transit Time, 100 % Gastric Emptying Time (Truncated at 240 Minutes), Small Bowel Transit Time, Colonic Transit Time as Determined by Wireless Motility Capsule (WMC)</title>
          <description>WMC is an ingestible telemetric capsule which measures pH, pressure and temperature to assess total gastric emptying time, small and large bowel transit time, colonic transit time, and whole gut transit time. The WMC was ingested immediately following the standard test meal for the oral breath test. Data was collected on a data logger, which was worn on a belt clip. The WMC passed naturally in the participantâ€™s stools between 2 and 5 days after ingestion. The parameters Whole bowel transit time, 100 % gastric emptying time (truncated at 240 minutes), small bowel transit time, colonic transit time were analyzed. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline value.</description>
          <population>All Subjects Population. Only those participants available at specified time points were analyzed.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>100% Gastric Emptying Time Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-159.9" spread="616.67"/>
                    <measurement group_id="O2" value="-240.3" spread="567.18"/>
                    <measurement group_id="O3" value="-323.8" spread="461.05"/>
                    <measurement group_id="O4" value="-381.0" spread="541.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100% Gastric Emptying Time Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-243.0" spread="500.49"/>
                    <measurement group_id="O2" value="-15.4" spread="502.80"/>
                    <measurement group_id="O3" value="-162.7" spread="558.96"/>
                    <measurement group_id="O4" value="-341.3" spread="599.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100% Gastric Emptying Time(Truncated) Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="27.95"/>
                    <measurement group_id="O2" value="3.7" spread="28.87"/>
                    <measurement group_id="O3" value="-15.8" spread="61.32"/>
                    <measurement group_id="O4" value="-65.5" spread="91.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100% Gastric Emptying Time(Truncated) Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="18.60"/>
                    <measurement group_id="O2" value="19.7" spread="42.47"/>
                    <measurement group_id="O3" value="-13.9" spread="42.34"/>
                    <measurement group_id="O4" value="-40.2" spread="68.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colonic Transit Time Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-331.3" spread="1349.11"/>
                    <measurement group_id="O2" value="-92.9" spread="1970.38"/>
                    <measurement group_id="O3" value="-170.5" spread="1723.01"/>
                    <measurement group_id="O4" value="-598.3" spread="1617.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colonic Transit Time Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-518.1" spread="2650.06"/>
                    <measurement group_id="O2" value="142.9" spread="1326.20"/>
                    <measurement group_id="O3" value="-29.4" spread="1702.69"/>
                    <measurement group_id="O4" value="-416.4" spread="1447.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Bowel Transit Time Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="118.39"/>
                    <measurement group_id="O2" value="-47.7" spread="94.33"/>
                    <measurement group_id="O3" value="15.7" spread="211.88"/>
                    <measurement group_id="O4" value="-6.6" spread="149.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Bowel Transit Time 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.4" spread="107.89"/>
                    <measurement group_id="O2" value="-57.3" spread="176.42"/>
                    <measurement group_id="O3" value="-7.1" spread="148.51"/>
                    <measurement group_id="O4" value="-28.6" spread="135.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Bowel Transit Time Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-527.6" spread="1489.02"/>
                    <measurement group_id="O2" value="-402.1" spread="2109.06"/>
                    <measurement group_id="O3" value="-493.1" spread="1987.51"/>
                    <measurement group_id="O4" value="-1002.5" spread="2045.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole Bowel Transit Time 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-777.6" spread="2644.80"/>
                    <measurement group_id="O2" value="-2.4" spread="1298.37"/>
                    <measurement group_id="O3" value="-233.5" spread="1850.91"/>
                    <measurement group_id="O4" value="-789.1" spread="1560.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to follow-up i.e., 14 days Â± 2 days post last dose (Day 28)</time_frame>
      <desc>All Subjects population was used to assess adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo tablets matching to GSK962040 administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="E2">
          <title>GSK962040 10 mg</title>
          <description>Participants received GSK962040 10 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="E3">
          <title>GSK962040 50 mg</title>
          <description>Participants received GSK962040 50 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
        <group group_id="E4">
          <title>GSK962040 125 mg</title>
          <description>Participants received GSK962040 125 mg tablets administered orally once daily for a period of 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Painful defaecation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Energy increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

